Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Lyra Therapeutics Inc logo
    LYRA

    Lyra Therapeutics Inc

    MaveScore 30 Low model confidence
    Last Price US$0.54 As of Jul 10, 2026
    Market Cap US$954700.0 Company size context
    7D Performance -23.95% Past 7 days
    1Y Performance N/A Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Dec 31, 2025

    192 days old

    Market price date

    Jul 10, 2026

    1 day old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 30 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Partial or delayed snapshot

    Quality

    7/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    12/25 Mixed

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    10/15 Mixed

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    0/15 Weak

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    1/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Highlights research candidates with supportive 3-month and 6-month price regimes.
    • Rewards less dilutive share behavior and enough size for liquid research coverage.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Lyra Therapeutics Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicin Read More

    Lyra Therapeutics Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Lyra Therapeutics Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Nov 12, 2025

    Quarterly result summary

    Revenue was $0M (-87% YoY). Net loss was -$6M (from $11.9M). Cash was $22.1M.

    Revenue $0M -87% YoY
    Net loss -$6M from $11.9M
    Cash $22.1M reported

    What changed

    • Revenue -87% YoY to $0M.
    • Net loss was -$6M (from $11.9M).

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-K Mar 31, 2026 SEC filing 10-Q Nov 12, 2025 SEC filing 8-K Nov 12, 2025 SEC filing 10-Q Aug 12, 2025 Earnings release Earnings release Aug 12, 2025 SEC filing 8-K Aug 12, 2025 SEC filing 8-K May 06, 2025 SEC filing 10-Q May 06, 2025 Earnings release Earnings release May 06, 2025 SEC filing 10-K Mar 13, 2025

    Recent News



    Lyra Therapeutics Crashes 30% After Announcing Stock Sale Agreement
    54 minutes ago
    Lyra Therapeutics raises $5 million in registered direct offering
    2 days ago
    Lyra Therapeutics Raises $5 Mln In Direct Offering, Eyes $9.8 Mln Via Warrant Exercises
    3 hours ago

    Earnings Per Share

    Score 3.00/5
    Lyra Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score -0.23/5
    Lyra Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Lyra Therape... LYRA US$954700
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Net Margin

    Score 0.30/5
    Lyra Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Lyra Therape... LYRA US$954700
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 2.50/5
    Lyra Therapeutics Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Lyra Therape... LYRA US$954700
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Lyra Therapeutics Inc logo

    Lyra Therapeutics Inc

    US$0.54

    US$954700.0

    -23.95%

    N/A